TY - JOUR
T1 - Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes
T2 - A patient-level pooled analysis
AU - Chaudhuri, Ajay
AU - Rosenstock, Julio
AU - Digenio, Andres
AU - Meneghini, Luigi
AU - Hollander, Priscilla
AU - McGill, Janet B.
AU - Dandona, Paresh
AU - Ilgenfritz, John
AU - Riddle, Matthew
PY - 2012/3
Y1 - 2012/3
N2 - Background: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. Methods: Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18years, diagnosed with type 2 diabetes for at least 6months, on metformin and/or sulphonylurea, and with A 1C ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides. Results: Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p<0.0003), 7.5% greater reduction in non-HDL-C (p<0.0001), and 7.8% greater reduction in total cholesterol (p<0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p<0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. Conclusion: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs.
AB - Background: The prevalence of dyslipidaemia and the risk of cardiovascular disease are elevated in patients with type 2 diabetes. This analysis compared the effects of insulin glargine versus thiazolidinediones (TZDs) on lipid profiles. Methods: Patient-level data were pooled from two randomized clinical studies. The population included 552 men and women aged >18years, diagnosed with type 2 diabetes for at least 6months, on metformin and/or sulphonylurea, and with A 1C ≥7.5% and <12.0% at screening. Lipid outcome measures included change from baseline in lipid levels [low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, triglycerides, and free fatty acids] and attainment of lipid goals for LDL-C, non-HDL-C, and triglycerides. Results: Both insulin glargine and TZDs improved lipid profiles from baseline values. Compared with TZDs, treatment with insulin glargine led to 7.9% greater reduction in LDL-C (p<0.0003), 7.5% greater reduction in non-HDL-C (p<0.0001), and 7.8% greater reduction in total cholesterol (p<0.0001), whereas the HDL-C increase with TZD was 7.6% greater than that with insulin glargine (p<0.0001). The percentage of patients attaining the lipid goals was comparable between insulin glargine and pioglitazone, but lower for rosiglitazone. Insulin glargine improved glycaemic control more than TZDs; however, insulin glargine caused more hypoglycaemia. Treatment with TZDs caused more weight gain and peripheral oedema. Conclusion: These findings suggest that the favourable effects of insulin glargine on plasma lipid profiles should be considered among the advantages of treatment with insulin glargine as they are for TZDs.
KW - Insulin glargine
KW - Lipids
KW - Thiazolidinediones
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=84858110025&partnerID=8YFLogxK
U2 - 10.1002/dmrr.1305
DO - 10.1002/dmrr.1305
M3 - Article
C2 - 22081557
AN - SCOPUS:84858110025
SN - 1520-7552
VL - 28
SP - 258
EP - 267
JO - Diabetes/Metabolism Research and Reviews
JF - Diabetes/Metabolism Research and Reviews
IS - 3
ER -